Skip to content

Trial · Interventional

CompletedNot applicableRegistry data

The Effects of Oxytocin Treatment on Social Touch

NCTNCT05265806 (opens ClinicalTrials.gov in a new tab)Other idUESTC-neuSCAN-79
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Not applicable
Enrollment
180 participants (actual)
Sponsor
University of Electronic Science and Technology of China · Other
Design
Randomized · Triple masking
Countries
1 country

China

Start
1 Sept 2021
Primary completion
1 Mar 2022
Completion
25 May 2022
First posted
4 Mar 2022
Last update posted
11 May 2023
Conditions
Healthy

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202120222023
  1. N/A

    The Effects of Oxytocin Treatment on Social Touch

    NCT05265806

    1 Sept 2021 to 25 May 2022

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The main aim of the study is to investigate the modulatory effects of oxytocin (24IU) administration on the affective processing of touch manipulated differently in gentle caress-like stroke vs. social massage with a moderate pressure.

Interventions

  • Intranasal oxytocinDrug
  • Oral oxytocinDrug
  • PlaceboDrug

Arms3

  • Experimental

    Intranasal oxytocin

    Participants will be randomly assigned to the administration of oxytocin intranasal spray (24 IU).

  • Experimental

    Oral oxytocin

    Participants will be randomly assigned to the administration of oxytocin lingual spray (24 IU).

  • Placebo comparator

    Placebo

    Participants will be randomly assigned to the administration of placebo.

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Neural index: fNIRS based measures of touch processing

    Time frame · 35-90 minutes after treatment administration

    Registry description

    fNIRS-based indices of neural processing of social touch after the oxytocin and placebo administration in response to each experimental condition.

  2. Behavioral index: ratings of the pleasantness, arousal, intensity and payment for the applied social touch

    Time frame · 50-90 minutes after treatment administration

    Registry description

    Ratings of perceived pleasantness, arousal, intensity and the willing to pay for the applied caress-like touch and massage after the oxytocin and placebo administration.

Secondary outcomes(5)

  1. Plasma oxytocin concentration

    Time frame · Basal concentration before treatment and altered level during 30-90 minutes after treatment administration

    Registry description

    Basal and altered blood oxytocin concentrations for different treatment groups before and 30 minutes after the administration as well as after each touch condition.

  2. Electrophysiological index: skin conductance responses (SCR)

    Time frame · 35-90 minutes after treatment administration

    Registry description

    SCR amplitudes during touch processing to further investigate oxytocin effects on each experimental condition compared with the placebo.

  3. Electrophysiological index: heart rate variability (HRV)

    Time frame · 35-90 minutes after treatment administration

    Registry description

    HRV reflecting the variability in consecutive heartbeats calculated from electrocardiography during touch processing to further investigate oxytocin effects on each experimental condition compared with the placebo.

  4. Questionnaire scores of autistic traits

    Time frame · Before the experiment

    Registry description

    The Autism Spectrum Quotient (ASQ) scores (0\~50, higher scores mean higher autistic trait) to investigate modulatory effects of autistic traits.

  5. Gender difference in the neural and behavioral index

    Time frame · 35-90 minutes after treatment administration

    Registry description

    Gender difference in the neural and behavioral response during the touch processing for different treatment groups.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2023

4 results

Oxytocin administration enhances pleasantness and neural responses to gentle stroking but not moderate pressure social touch by increasing peripheral concentrations.

Chen et al. 2023eLifecited by 14

PMID 37171081PMC10229136DOI 10.7554/elife.85847PUB-37171081

CC BY4 results
Download PDFSee results (4)

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • DerivedYamagata T, Ogiwara I, Tatsukawa T, Suzuki T, Otsuka Y, Imaeda N, Mazaki E, Inoue I, Tokonami N, Hibi Y, Itohara S, Yamakawa K. Scn1a-GFP transgenic mouse revealed Nav1.1 expression in neocortical pyramidal tract projection neurons. Elife. 2023 May 23;12:e87495. doi: 10.7554/eLife.87495. PMID 37219072

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 30 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Healthy subjects without any past or present psychiatric or neurological disorders and without any current psychotherapeutic medication. Exclusion Criteria: * Any history of brain injury, psychiatric/physical illness, alcohol/substance abuse, or other major health concern.

PepBank is a research reference. Talk to a doctor before you use any peptide.